• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Day One Biopharmaceuticals Inc (NQ: DAWN )

    14.01 -0.19 (-1.34%)
    Streaming Delayed Price Updated: 10:35 AM EDT, Aug 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 32,197
    Open 14.25
    Bid (Size) 13.99 (3)
    Ask (Size) 14.02 (2)
    Prev. Close 14.20
    Today's Range 13.94 - 14.25
    52wk Range 9.670 - 18.07
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
    Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
    Via InvestorPlace
    Topics Economy
    Exposures Economy
    Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga

    Performance

    YTD
    -3.51%
    -3.51%
    1 Month
    -5.78%
    -5.78%
    3 Month
    -4.17%
    -4.17%
    6 Month
    -5.02%
    -5.02%
    1 Year
    +2.04%
    +2.04%

    More News

    Read More
    DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Oversubscribed $175.0 Million Private Placement
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Analyst Ratings for Day One Biopharmaceutical
    Via Benzinga
    The Latest Analyst Ratings for Day One Biopharmaceutical
    Via Benzinga
    Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
    Via Talk Markets
    Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Sale of Priority Review Voucher for $108 Million
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
    Via InvestorPlace
    Day One Reports First Quarter 2024 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Two New Appointments to Board of Directors
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Dow Up Over 340 Points As Stocks Snap Back
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.